5 Takeaways From FDA's Off-Label Promo Forum

The U.S. Food and Drug Administration on Wednesday heard sharply divergent views about off-label promotion of drugs and medical devices, with manufacturers and BigLaw attorneys urging more leeway while consumer advocates...

Already a subscriber? Click here to view full article